Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology · Savannah, GA
NPI
1285672329
Since 2006
Specialty
Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology
Code 2084N0402X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
6602 Waters Ave, Building C
Savannah, GA, 31406
Phone (912) 354-7676
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.4M
180,251 services
Medicare patients, 2024
695
Average age 71
Drug cost, 2024
$4.4M
5,734 prescriptions
Company payments, 2025
$394K
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John M Hemphill was code J0174 (injection, lecanemab-irmb, 1 mg), 85,300 times for 29 patients. In total John M Hemphill billed 180,251 services in 89 codes, and Medicare paid $1.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-05-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0174 Injection, lecanemab-irmb, 1 mg | Office | 85,300 | 29 | $1.03 | $88K |
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 27,900 | 46 | $4.92 | $137K |
| J3032 Injection, eptinezumab-jjmr, 1 mg | Office | 15,800 | 45 | $14.05 | $222K |
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 9,130 | 12 | $4.09 | $37K |
| A9585 Injection, gadobutrol, 0.1 ml | Office | 3,440 | 38 | $0.24 | $822 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 822 | 494 | $11.77 | $9,673 |
| 99214 Office E&M - Established | Office | 428 | 303 | $79.15 | $34K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 399 | 113 | $44.29 | $18K |
| 99213 Office E&M - Established | Office | 287 | 215 | $57.13 | $16K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 191 | 83 | $0.50 | $96.33 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 162 | 63 | $33.66 | $5,452 |
| 64615 Musculoskeletal | Office | 143 | 46 | $104.64 | $15K |
| 96413 Chemotherapy Administration | Office | 138 | 44 | $89.78 | $12K |
| 70551 MRI/MRA - Head and Neck | Office | 109 | 72 | $86.55 | $9,433 |
| 99215 Office E&M - Established | Office | 106 | 91 | $128.32 | $14K |
By year: 2022 $1.3M for 85,483 services; 2023 $1.2M for 89,278 services; 2024 $1.4M for 180,251 services.
Medicare prescription drug claims, 2024
In 2024, the drug John M Hemphill prescribed most often to Medicare patients was Levetiracetam, with 360 prescriptions and refills. In total John M Hemphill wrote 5,734 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levetiracetam Generic | 360 | 622 | 81 | $12K |
| Gabapentin Generic | 305 | 501 | 80 | $6,026 |
| Topiramate Generic | 271 | 497 | 62 | $2,603 |
| Baclofen Generic | 256 | 436 | 57 | $4,415 |
| Donepezil Hcl Generic | 233 | 408 | 60 | $2,042 |
| Tizanidine Hcl Generic | 196 | 312 | 47 | $2,932 |
| Quetiapine Fumarate Generic | 155 | 203 | 32 | $2,828 |
| Aimovig Autoinjector Erenumab-Aooe | 140 | 168 | 23 | $122K |
| Carbidopa-Levodopa Carbidopa/Levodopa | 138 | 207 | 29 | $2,583 |
| Sumatriptan Succinate Generic | 125 | 159 | 29 | $2,105 |
| Lacosamide Generic | 122 | 168 | 23 | $16K |
| Amitriptyline Hcl Generic | 118 | 234 | 30 | $1,643 |
| Lamotrigine Generic | 116 | 244 | 25 | $2,671 |
| Propranolol Hcl Er Propranolol Hcl | 113 | 214 | 30 | $4,311 |
| Rizatriptan Rizatriptan Benzoate | 107 | 125 | 31 | $1,440 |
Brand drugs: 1,032 claims; generic drugs: 4,679 claims; opioid claims: 32.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John M Hemphill $394K ($394K in general payments such as food, travel and fees) from 41 companies. The largest payer was Eisai Inc. with $128K.
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. 4523.T | 123 | $128K |
| Amgen Inc. AMGN | 54 | $50K |
| Alexion Pharmaceuticals, Inc. AZN | 37 | $42K |
| TG Therapeutics, Inc. TGTX | 29 | $33K |
| Genzyme Corporation SNY | 16 | $33K |
| Argenx US, Inc. ARGX | 32 | $27K |
| EMD Serono, Inc. MRK.DE | 24 | $26K |
| E.R. Squibb & Sons, L.L.C. BMY | 12 | $21K |
| Abbvie Inc. ABBV | 45 | $19K |
| Pfizer Inc. PFE | 12 | $6,801 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.